Fibrillin-1 is a novel ligand of the epidermal growth factor receptor promoting mesangial cell activation and glomerulosclerosis

doi.org/10.1016/j.kint.2026.01.018

#MedSky #NephSky #glomerulosclerosis

Clinical Applications of Artificial Intelligence in Autosomal Dominant Polycystic Kidney Disease Abstract. Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney disorder leading to kidney failure. Recent advancements in

Clinical Applications of Artificial Intelligence in Autosomal Dominant Polycystic Kidney Disease @ndt-era.bsky.social

oup2-idp.sams-sigma.com/authorize?au...

New findings suggest a steady increase in the prevalence of kidney failure with replacement therapy worldwide over the past 3 decades. Read more in #ASNKidneyNews kidney.pub/KN1710-24

2025 AJKD Editors' Choice Award winning article: Genetic Characterization of Kidney Failure of Unknown Etiology in Spain: Findings From the GENSEN Study

bit.ly/3WeEZ72

#VisualAbstract

📖 This weekend don't miss our @kidneyint.bsky.social #ISNFridaySelection: Patient preferences for kidney failure treatments www.kidney-internati...

Register for our upcoming webinar in 2026✨

📌Registration is FREE

www.eeds.com/portal_live_...

www.mdpi.com/2072-6643/17...

Artificial Intelligence in ADPKD: Transforming Diagnosis, Risk Stratification, and Therapeutic Interventions
SA-PO0555 : Journal of the American Society of Nephrology #KidneyWk

journals.lww.com/jasn/fulltex...

Did you know Women in Nephrology offers a Mentor Match program? Whether you want to be a mentor or find one, WIN helps you connect with your perfect match. If you are a member, apply today!
#WIN #MentorMatch

Executive summary of the #KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (#IgAN) and Immunoglobulin A Vasculitis (#IgAV)

doi.org/10.1016/j.kint.2025.04.003

#OpenAccess #MedSky #NephSky @kdigo.org

The Mayo Imaging Classification of ADPKD description (left panel) and imaging examples (right panel) with examples (right panel) of (a, b) subclass 1A and 1E, (c-f) subclass 2A, and (g, h) subclass 2B. Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; TKV, total kidney volume. Reproduced with permission of the copyright holder (Kidney Disease: Improving Global Outcomes) from Kidney Disease: Improving Global Outcomes (KDIGO) ADPKD Work Group. KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Kidney Int. 2025;107(suppl 2S):S1-S239. doi:10.1016/j.kint.2024.07.009

Core Curriculum by Craig E. Gordon et al:

Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2025
bit.ly/465twwK (FREE)

Empowering the Next Generation of Nephrologists: Trainee Opportunities in #GlomCon Ecosystem from @asnpublications.bsky.social @glomcon.org @bettercallseeth.bsky.social @saynanorouzi.bsky.social @nephrologista.bsky.social @poyanmehr.org
#Nephpearls #NephSky

👉 pubmed.ncbi.nlm.nih.gov/41105470/

Did you miss #GlomCon Hawaii? Don't worry, I took the hit and flew to Hawaii for a week so I could give all of you a summary of what went down. Read all about it...

Thank you NKF for having us at the #NKFSoCalKidneyWalk 🧡
Today, we hosted a booth to recruit for our “Kidney Check” study, proudly sponsored by the IgAN Foundation.

IgG4-related tubulointerstitial nephritis with negative contrast-enhanced computed tomography: diagnostic insights from 18F-fluorodeoxyglucose–positron emission tomography/computed tomography
doi.org/10.1016/j.kint.2025.02.031

#KINephrologyImage #NephSky #MedSky #KidneyPath #RenalPath #kidneybiopsy

ALECT2 amyloidosis in a patient with myeloma cast nephropathy

Concomitant renal amyloidosis, typically AL, can be rarely seen in patients with myeloma cast nephropathy.

doi.org/10.1016/j.kint.2024.12.024

#NephSky #MedSky #NephrologyImage #renalpath #kidneypath #kidneybiopsy #multiplemyeloma

Artificial intelligence and perspective for rare genetic kidney diseases
Chen et al.

doi.org/10.1016/j.kint.2025.03.033

#OpenAccess #KIMiniReview #artificialintelligence

Find more articles in KI Kidney Genomic Medicine collection:
www.kidney-international.org/content/kidn...

Executive summary of the #KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy ( #IgAN) and Immunoglobulin A Vasculitis ( #IgAV)

doi.org/10.1016/j.kint.2025.04.003

#OpenAccess #MedSky #NephSky #glomerulardisease @imperialcollegeldn.bsky.social

The one and only @kidneyboy.bsky.social representing #NephJC at #GlomConHawaii 🌊
#NephSky

Is hepatotoxicity still a concern with long-term Tolvaptan use? This #ASNKidney360 review summarizes the data from clinical trials and presents real world evidence: kidney.pub/KID0934

Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Assessing the Efficacy and Safety of Felzartamab for IgA Nephropathy

doi.org/10.1016/j.kint.2025.05.028

#OpenAccess #IgAN #felzartamab #IgANephropathy

Cardiovascular Complications in Autosomal Dominant Polycystic Kidney Disease Autosomal dominant polycystic kidney disease (ADPKD), primarily caused by mutations in the PKD1 or PKD2 gene, is among the most common hereditary kidney diseases worldwide and is associated with signi...

Cardiovascular Complications in Autosomal Dominant Polycystic Kidney Disease - Kidney International Reports @kireports.bsky.social
www.kireports.org/article/S246...

AI vs. Nephrologists: Diabetic Nephropathy Q&A This video reviews a cross-sectional study comparing how artificial intelligence models like ChatGPT and Google Gemini align with nephrologists when answerin...

Amir Abdipour from #LomaLindaUniversityMedicalCenter discusses his study on the alignment of AI models with nephrologists when answering patient questions about #diabeticnephropathy.

Watch now: www.youtube.com/watch?v=yqDP...

Read the full article: diabetes.jmir.org/2025/1/e65846/

#AI #LLU

Agreement Between AI and Nephrologists in Addressing Common Patient Questions About Diabetic Nephropathy: Cross-Sectional Study Diabetic nephropathy (DN) is one of the most frequent and severe complications of diabetes mellitus that requires early reduction for the individuals most at risk. Effective intervention and managemen...

diabetes.jmir.org/2025/1/e65846

AI vs. Nephrologists: Diabetic Nephropathy Q&A YouTube video by JMIR Publications

Watch this one-minute video highlighting our paper published in @jmirpub.bsky.social

www.youtube.com/watch?v=yqDP...

Long-Term Data Support Efficacy and Safety of Zigakibart for IgAN | Docwire News Data from a phase 1/2 study demonstrated that the anti-APRIL zigakibart reduced proteinuria and stabilized kidney function of patients with IgA nephropathy (IgAN) at 100 weeks.

Long-term data presented at #ERA25 on Thursday support the efficacy and safety of zigakibart for IgAN. #nephrology #nephsky #iganephropathy #igan www.docwirenews.com/post/long-te...

Only two weeks left❗️
Mark your calendar ✔️and register today. #EndPKD

www.eeds.com/portal_live_...

Real-world challenges in the use of tolvaptan for ADPKD lead to high discontinuation rates and dosage adjustments, underscoring the need for standardized and improved management strategies to enhance tolerability and adherence. https://bit.ly/KID0816
@shelliefravel.bsky.social
#ASNKidney360

📣Exciting News!

We are thrilled to announce our upcoming Loma Linda Polycystic Kidney Disease Webinar: Expert Insights on Navigating the KDIGO 2025 ADPKD Guidelines.

✅FREE Registration
📅Friday, June 6, 2025
🕥 8:30 AM - 1:00 PM (Pacific Time)

🔗Register here: www.eeds.com/portal_live_...

Agreement Between AI and Nephrologists in Addressing Common Patient Questions About Diabetic Nephropathy: Cross-Sectional Study Diabetic nephropathy (DN) is one of the most frequent and severe complications of #diabetes mellitus that requires early reduction for the individuals most at risk. Effective intervention and management of DN requires a patient's deep insight and helpful information. Patients require accurate information to obtain prevention advice about their kidney disease to make appropriate decisions; individuals may seek artificial intelligence (AI) as online sources instead of communicating with clinicians. Therefore, to evaluate ChatGPT and Google Bard's capabilities in providing accurate information regarding DN compared to nephrologists, we assessed their performance in answering questions related to DN. Our study revealed AI would not eliminate the need for open and detailed discussion with healthcare professionals regarding medical concerns and treatment plans, as they indicated inconsistencies in responses. Additionally, it is imperative to provide real-time health information updates to meet the needs of individuals with DN.

New JMIR Diabetes: Agreement Between AI and Nephrologists in Addressing Common Patient Questions About Diabetic Nephropathy: Cross-Sectional Study